ReviewInternational journal of oncology2023
PD‑1/PD‑L1 immune checkpoint inhibitors in neoadjuvant therapy for solid tumors (Review).
Review in International journal of oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 4 syntheses or guidelines pooled it, 22 citations in OpenAlex.
- Safety evaluation of PD-1/PD-L1 therapies for treatment of NSCLC: a systematic review, bayesian network meta-analysis, and cost-effectiveness analysis.BMC cancer · 2026Pooled it
- Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Current Status, Challenges, and Future Perspectives.Cancer medicine · 2026Pooled it
- Efficacy and safety of immune checkpoint inhibitors in recurrent or metastatic head and neck squamous cell carcinoma: A systematic review and meta-analysis of randomized clinical trials.Cancer medicine · 2023Pooled it
- Chronic immune-related adverse events in patients with cancer receiving immune checkpoint inhibitors: a systematic review.Journal for immunotherapy of cancer · 2023Pooled it
- The role of tumor metabolic reprogramming in acquired anti-PD-1/PD-L1 resistance.Translational lung cancer research · 2026Review
- Clinical characteristics and management of PD-1/PD-L1 inhibitor-induced secondary adrenal insufficiency.Endocrine connections · 2026Article
- Current status of management of immune-related adverse events and practical needs for oncologist education.Cancer biology & medicine · 2025Review
- The expression patterns and prognostic significance of PD-1 and TIM-3 on T cells and the differentiated subsets in acute myeloid leukemia.Annals of hematology · 2025Article
- Programmed cell death receptor 1 inhibitor Pembrolizumab in the treatment of advanced gastric cancer.World journal of gastrointestinal surgery · 2025Article
- Advances in Melanoma and Skin Cancers.International journal of molecular sciences · 2025Article
- Emerging strategies in colorectal cancer immunotherapy: enhancing efficacy and survival.Frontiers in immunology · 2025Review
- LncRNA HOXB-AS4 Promotes Tumor Malignant Phenotype in Head and Neck Squamous Cell Carcinoma and Serves as a Prognosis Marker.Journal of Cancer · 2025Article
- Peripheral TNF-α and CD8Breast cancer (Dove Medical Press) · 2025Article
- CD39Frontiers in oncology · 2025Review
- ICOSLG Is Associated with Anti-PD-1 and Concomitant Antihistamine Treatment Response in Advanced Melanoma.International journal of molecular sciences · 2024Article
- Review
- Article
- Pathological examination of factors involved in PD-L1 expression in patients with oral tongue squamous cell carcinoma.Maxillofacial plastic and reconstructive surgery · 2024Article
- Non‑coding RNA: A promising diagnostic biomarker and therapeutic target for esophageal squamous cell carcinoma (Review).Oncology letters · 2024Review
- Durvalumab Plus Gemcitabine and Cisplatin Versus Gemcitabine and Cisplatin in Biliary Tract Cancer: a Real-World Retrospective, Multicenter Study.Targeted oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A comprehensive search regarding programmed cell death protein 1 (PD‑1)/programmed death‑ligand 1 (PD‑L1) inhibitor monotherapy or combination therapy in neoadjuvant settings of 11 types of solid cancer was performed using the PubMed, Cochrane and Embase databases, and the abstracts of various conferences were screened. Data presented in 99 clinical trials indicated that preoperative treatment with PD‑1/PD‑L1 combined therapy, particularly immunotherapy plus chemotherapy, could achieve a higher objective response rate, a higher major pathologic response rate and a higher pathologic complete response rate, as well as a lower number of immune‑related adverse events compared with PD‑1/PD‑L1 monotherapy or dual immunotherapy. Although PD‑1/PD‑L1 inhibitor combination caused more treatment‑related adverse events (TRAEs) in patients, most of the TRAEs were acceptable and did not cause marked delays in operation. The data suggest that patients with pathological remission after neoadjuvant immunotherapy exhibit improved postoperative disease‑free survival compared with those without pathological remission. Further studies are still required to evaluate the long‑term survival benefit of neoadjuvant immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.